Nanotechnology Now

Our NanoNews Digest Sponsors





Heifer International

Wikipedia Affiliate Button


android tablet pc

Home > Press > Stellar Biotechnologies Announces CDN$ 1.05M Financing and Retires 1.66M Shares

Abstract:
Stellar Biotechnologies, Inc. (Stellar) is pleased to announce that it has agreed to complete a CDN$ 1.05M private placement subject to acceptance by the TSX Venture Exchange, and, also, the cancellation of 1,661,241 shares of the Company's outstanding common stock.

Stellar Biotechnologies Announces CDN$ 1.05M Financing and Retires 1.66M Shares

Port Hueneme, CA | Posted on September 30th, 2010

Stellar Agrees to Complete Financing

Subject to acceptance by the TSX Venture Exchange, Stellar has agreed to complete its non-brokered, private placement of 3,000,000 Units at CDN$ 0.35 per Unit for CDN$ 1,050,000, with a single, long-term, strategic investor for the specific purpose of advancing a new product line, sought after by our customers and potential customers, that was not envisioned in the previous budget.

Each Unit is composed of one common share and one 1/2 warrant, each warrant for purchase of a common share at $0.50 until eighteen months from the issuing of the shares upon completion. The shares issued in the Private Placement are subject to a 4 month and 1 day hold period from that date, and a finder's fee will be payable subject to the regulations of the TSX Venture Exchange.

Stellar Cancels 1,661,241 of Outstanding Shares

In a pre-arranged deal, Stellar cancelled 1,661,241 common shares on payment by the Company of approximately US$ 0.075 (7.5 cents)/share. Stellar believes the retirement of these shares benefits the Company and all shareholders by reducing the number of outstanding shares and lowering dilution.

Darrell Brookstein, Director & Executive VP, Business Development & Finance of Stellar, said, "We were able to retire shares to our treasury at a steep discount to the market, and, pending acceptance by the Exchange, sell Units to a long-term, significant shareholder with strong coastal development experience in an area that is complementary to our southern California location. We view the ability to raise this additional capital now as significant -- advancing and building on our new market opportunity, while forging a strong relationship with a committed financier and shareholder."

####

About Stellar Biotechnologies, Inc.
Stellar Biotechnologies, Inc. (TSX-V: KLH) (PINKSHEETS: SBOTF) (www.StellarBiotechnologies.com) is a world leader in sustainable manufacturing of pharmaceutical grade immune carrier proteins (ICP), particularly with regard to the present most important pharmaceutical protein in this class, KLH (Keyhole Limpet Hemocyanin). This ancient evolutionary protein has a highly complex structure that makes it ideal for use in human and animal vaccines and diagnostic products. With partners and customers, its flagship Stellar KLH products are in the clinic, and on the way to being established as the only sustainable, long-term pharmaceutical source.

Statements in this press release other than purely historical factual information, including statements relating to revenues or profits, or the Company's future plans and objectives, or expected sales, cash flows, and capital expenditures constitute forward-looking statements. Forward-looking statements are based on numerous assumptions and are subject to all of the risks and uncertainties inherent in the Company's business, including risks inherent in the technology history. There can be no assurance that such forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. This news release does not constitute an offer to sell, or a solicitation of an offer to buy any of the Company's securities set out herein in the United States, or to, or for the benefit or account of, a U.S. person or person in the United States. Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

For more information, please click here

Contacts:
Darrell Brookstein
Executive VP
Business Development & Finance

Copyright © Marketwire

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

High-Performance, Low-Cost Ultracapacitors Built with Graphene and Carbon Nanotubes: Future devices based on technology could bridge gap between batteries and conventional capacitors in portable electronics and hybrid electric vehicles April 23rd, 2014

Guo Lab Shows Potential of RNA as Heat-resistant Polymer Material for Nanoarchitectures April 23rd, 2014

Vacuum Ultraviolet Lamp of the Future Created in Japan: First Solid-State Vacuum UV Phosphor, Described in APL-Materials, Promises Smaller, Safer, Longer Lasting, Low Power Lamps for Industrial Applications April 22nd, 2014

Global leader in solar cell manufacturing eyes New York for major expansion outside of Japan: CNSE and Solar Frontier Explore $700 Million Investment, Job Creation in New York State April 22nd, 2014

VC/Funding/Angel financing/Loans/Leases/Crowdfunding

Harris & Harris Group Notes the Receipt of Proceeds From the Sale of Molecular Imprints' Semiconductor Business to Canon April 22nd, 2014

Harris & Harris Group Continues Its Blog Series to Highlight Most Impactful Portfolio Companies With Champions Oncology, Inc. April 17th, 2014

Premier Healthcare Pitch Competition comes to Atlanta this May April 12th, 2014

Harris & Harris Group Notes Mersana's Collaboration Agreement With Subsidiary of Takeda Pharmaceutical Co. April 8th, 2014

Nanomedicine

Cloaked DNA nanodevices survive pilot mission: Successful foray opens door to virus-like DNA nanodevices that could diagnose diseased tissues and manufacture drugs to treat them April 22nd, 2014

Berkeley Lab Researchers Demonstrate First Size-based Chromatography Technique for the Study of Living Cells April 22nd, 2014

Amino-functionalized carbon nanotubes act as a carrier for nerve growth factor April 21st, 2014

Newly-Produced Bone Cement Able to Carry Medicine April 21st, 2014

Announcements

High-Performance, Low-Cost Ultracapacitors Built with Graphene and Carbon Nanotubes: Future devices based on technology could bridge gap between batteries and conventional capacitors in portable electronics and hybrid electric vehicles April 23rd, 2014

Guo Lab Shows Potential of RNA as Heat-resistant Polymer Material for Nanoarchitectures April 23rd, 2014

Harris & Harris Group Notes the Receipt of Proceeds From the Sale of Molecular Imprints' Semiconductor Business to Canon April 22nd, 2014

National Space Society Congratulates SpaceX on the Success of CRS-3 and the First Flight of the Falcon 9R April 22nd, 2014

NanoNews-Digest
The latest news from around the world, FREE







  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More














ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project







© Copyright 1999-2014 7th Wave, Inc. All Rights Reserved PRIVACY POLICY :: CONTACT US :: STATS :: SITE MAP :: ADVERTISE